Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is released from the intestine in response to food intake and plays a crucial role in regulating blood sugar levels. It stimulates insulin secretion from pancreatic beta cells, suppresses glucagon secretion (which helps lower blood sugar levels), slows down gastric emptying, and reduces appetite.
Semaglutide works by binding to and activating GLP-1 receptors in various tissues, including pancreatic beta cells, where it enhances insulin secretion in a glucose-dependent manner. This means that semaglutide primarily acts when blood sugar levels are elevated, helping to lower them without causing hypoglycemia (low blood sugar) when levels are normal. It also suppresses glucagon secretion, which further contributes to its blood sugar-lowering effects.
| Property | Value |
|---|---|
| COA | Available |
| Shelf Life | 2 Years |
| Shipping Method | Air(UPS, FedEx, TNT, EMS) Or Sea |
| Storage Conditions | Store At 2-25°C |
| Active Ingredient | Semaglutide |
| Form | 99% Raw Powder |
| Test Method | HPLC UV |
| Indication | Weight Loss |
| CAS | 910463-68-2 |
| Product Name | Semaglutide Peptide Weight Loss |
1. Weight loss: Semaglutide has been associated with significant weight loss in people with type 2 diabetes, as well as in individuals with obesity. This weight loss is thought to result from a combination of reduced appetite, slowed gastric emptying, and increased energy expenditure.
2. Cardiovascular benefits: Clinical trials have demonstrated that semaglutide can reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes who are at high cardiovascular risk. This cardiovascular benefit is particularly significant given the increased risk of heart disease in individuals with diabetes.
3. Potential benefits in non-alcoholic fatty liver disease (NAFLD): Preliminary research suggests that semaglutide may have beneficial effects on liver health in individuals with NAFLD, a condition characterized by the accumulation of fat in the liver.
For high value products, please select air shipping and express delivery for safety.
Shandong Longilat Biotechnology Co., Ltd was established in 2015. It is a high-tech professional and technological enterprise integrating R & D, production, and sales.
Longilat 's main products are food additives, plant extracts, cosmetic raw materials, feed additives, animal extract, amino acids and vitamins. Most of our products are derived from natural plants. Marketing services are available in many countries around the world.
